

## Perfluorooctanesulfonate (PFOS) activates mast cell-mediated allergic reaction

Lee YJ\*, Park SJ, Yang JH

Department of Pharmacology/Toxicology, Catholic University of Daegu, School of Medicine, Daegu, Republic of Korea, 42472

### Introduction

Millions of people worldwide are suffering from allergic diseases such as rhinitis, asthma, and atopic dermatitis. Many epidemiological studies have suggested that environmental contaminants are one of the important contributing factors for the pathogenesis of allergic disease [1,2]. In particular, exposure to environmental toxicants during perinatal period has been suggested to be responsible for the alteration in immune functions and increase development of allergic phenotype because this period is a critical time for the development of immune system and [3,4].

Perfluoroalkyl compounds (PFCs) have been widely used in industrial and various consumer products since 1950s. Due to their extreme stability, PFCs are accumulated in environment and accumulate in human via food web and are considered environmental pollutants [5]. Among these compounds, perfluorooctane sulfonate (PFOS) is the most extensively distributed and studied member of PFC family. PFOS has been detected in serum from general population as well as in umbilical cord and breast milk [6-8], indicating human exposure to PFCs during perinatal period. Recent animal and human studies have shown that PFCs have immunotoxic effects [9,10]. It has been reported that PFCs exposure reduced immune responses to childhood vaccination with rubella and booster vaccination with diphtheria and tetanus in adults [11,12]. In addition, positive correlation between serum levels of PFCs including PFOA, PFOS and PFHxS and self-reported food allergies has been reported [13]. However, there are very limited studies on the effects of PFCs on allergic reactions.

Mast cells play a central role in allergic diseases. The activation of mast cells occurs via IgE/Ag-dependent and -independent manner. The activation of mast cells involves the activation of multiple signaling pathways including phospholipase C $\gamma$  (PLC $\gamma$ ), mitogen-activated protein kinases, Akt and NF- $\kappa$ B, leading to release of preformed mediators by degranulation and *de novo* synthesis of lipid mediators and cytokines [14,15].

In the present study, we have examined the effects of short-term PFOS exposure on allergic using bone marrow-derived mast cells (BMMCs).

### Materials and Methods

**Preparation of mouse BMMCs.** BMMCs were isolated from 6~7-wk-old male Balb/cJ, as described previously [16]. Briefly, BMMCs were cultured in RPMI 1640 medium containing 10% (v/v) FBS, 100 U/ml penicillin (Thermo Fisher Scientific), 10 mM HEPES (Sigma-Aldrich), 100  $\mu$ M MEM non-essential amino acid solution (Invitrogen) and 20% (w/v) PWM-SCM (pokeweed mitogen-spleen cell conditioned medium) as a source of IL-

3. For cell stimulation with IgE/Ag,  $1 \times 10^6$  cells/ml were sensitized with 500 ng/ml mouse anti-DNP IgE (Sigma-Aldrich) overnight and then stimulated with 100 ng/ml DNP-HAS (Sigma-Aldrich) for 15 min at 37°C.

**Immunoblotting.** Cells were washed twice with ice-cold PBS and lysed in SDS-sample buffer containing 1% (v/v) NP-40, 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 2 µg/ml leupeptin, and 1 µg/ml pepstatin A for 30 min on ice. Lysates were centrifuged at 14,000g for 20 min at 4°C and resulting supernatants were subjected to immunoblotting.

**β-hexosaminidase release assay.** Mast cell degranulation was evaluated by measuring β-hexosaminidase release as described previously [17].

**PGD<sub>2</sub> and LTC<sub>4</sub> measurement.** The levels of PGD<sub>2</sub> and LTC<sub>4</sub> following mast cell activation were quantified with respective immunoassay kits (Cayman Chemicals, Ann Arbor, Mich).

## Results and Discussion

The activation of mast cells results in the release of various mediators responsible for the development of allergic inflammatory responses. The effect of PFOS on β-hexosaminidase (β-Hex) release was examined. BMBCs were treated with 30 µM of PFOS and 50 µM bisphenol A (BPA) for 1 h or stimulated with IgE/Ag for 15 min. IgE/Ag-stimulated mast cells (DNP-HAS) induced a robust increase in β-Hex release (17 %). PFOS significantly increased β-Hex release (7.8 %) compared to control (2.4 %). The effect of PFOS was compared to that of BPA, another environmental pollutant known as having immunotoxic properties. As reported by others [18,19], BPA also significantly increased β-Hex release (5.1 %) (Fig 1A). The effect of PFOS was concentration dependent (Fig 1B). Similarly, PFOS significantly increased the synthesis of leukotriene C<sub>4</sub> (LTC<sub>4</sub>) and prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) (Fig 2, 3). These results suggested that short-term PFOS exposure significantly increased mast cell degranulation via IgE/Ag-independent manner with comparable extent to that of BPA.

The signaling cascade involved in IgE/Ag-stimulated mast cell activation has been well established. The binding of IgE/Ag on mast cells induce the activation of proximal receptor-associated tyrosine kinases including Lyn, Fyn and Syk, followed by phosphorylation of PLCγ and PI3K. The activation of PLCγ promotes Ca<sup>2+</sup> mobilization and protein kinase C (PKC) activation. PI3K converts PIP<sub>2</sub> to PIP<sub>3</sub>, resulting in activation of various signaling molecules such as Btk, Akt and PDK1. These signaling pathways converge on the activation of downstream signaling pathways including MAP kinases (MAPK) and IKK- nuclear factor κB (NF-κB), which mediate degranulation and production of lipid mediators. Both PFOS (3 nM -30 µM) and BPA increased the activities of PLCγ, IKK, Akt, p38 and ERK (Fig 4). This result suggests PFOS may share common signaling pathways involved in IgE/Ag stimulated mast cell activation. .


## Acknowledgment

This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education(2014R1A1A2056565), South Korea.

## References

1. Dunlop J, Matsui E and Sharma HP (2016) *Immunol Allergy Clin North Am*, **36(2)** 367-377.
2. Yang SN, Hsieh CC, Kuo HF, Lee MS, Huang MY, Kuo CH, Hung CH (2014) *Allergy Asthma Immunol Res*, **6(6)** 478-484.
3. Holladay S and Smialowicz R (2000) *Environ Health Perspect*, **108** 463–473.
4. Martino D and Prescott S (2011) *Chest*, **139** 640–647.
5. Lau C, Anitole K, Hodes C, Lai D, Pfähles-Hutchens A and Seed J (2007) *Toxicol Sci*, **99** 366-394.
6. Lee YJ, Kim MK, Bae J and Yang JH (2013) *Chemosphere*, **90** 1603-1609.
7. Kato K, Wong LY, Jia LT, Kuklenyik Z and Calafat AM (2011) *Environ Sci Technol*, **45** 8037-8045.
8. Kärman A, Ericson I, van Bavel B, Darnerud PO, Aune M, Glynn A, Lignell S and Lindström G (2007) *Environ Health Perspect*, **115** 226-230.
9. Peden-Adams MM, Keller JM, Eudaly JG, Berger J, Gilkeson GS and Keil DE (2008) *Toxicol Sci*, **104(1)** 144-154.
10. Grandjean P, Heilmann C, Weihe P, Nielsen F, Mogensen UB, Budtz-Jørgensen E (2016) *Environ Health Perspect*.
11. Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, van Loveren H, Løvik M and Nygaard UC (2013) *J Immunotoxicol*, **10(4)** 373-379.
12. Kielsen K, Shamim Z, Ryder LP, Nielsen F, Grandjean P, Budtz-Jørgensen E and Heilmann C (2016) *J Immunotoxicol*, **13(2)** 270-273.
13. Buser MC and Scinicariello F (2016) *Environ Int*, **88** 74-79.
14. Gilfillan AM and Rivera J (2009) *Immunological reviews*, **228** 149-169.
15. Galli SJ and Tsai M (2012) *Nature medicine*, **18** 693-704.
16. Hwang SL, Li X, Lu Y, Jin Y, Jeong YT, Kim YD, et al. (2013) *The Journal of allergy and clinical immunology*, **132** 729-736 e712.
17. Son JK, Son MJ, Lee E, Moon TC, Son KH, Kim CH, et al. (2005) *Biol Pharm Bull*, **28** 2181–2184.
18. Lee J, Lee SJ and Lim KT (2012) *Food and Chemical Toxicology*, **50** 2109-2117.
19. O'Brien E, Dolinoy DC and Mancuso P (2014) *Journal of Immunotoxicology*, **11** 84-89.

(A)



(B)





Fig1. The effects of PFOS, BPA and IgE/Ag (DNP-HAS) on mast cell degranulation

(A)



(B)




Fig2. The effects of PFOS, BPA and IgE/Ag (DNP-HAS) on LTC<sub>4</sub> release




Fig3. The effects of PFOS and IgE/Ag (DNP-HAS) on PGD<sub>2</sub> release




Fig4. The effects of PFOS and BPA on phosphorylation of signal molecules